519 related articles for article (PubMed ID: 24515599)
1. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
Woloshin S; Schwartz LM
JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
[TBL] [Abstract][Full Text] [Related]
2. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
3. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
[TBL] [Abstract][Full Text] [Related]
5. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
6. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Shyh G; Cheng-Lai A
Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
[TBL] [Abstract][Full Text] [Related]
7. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
8. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
[TBL] [Abstract][Full Text] [Related]
9. Topiramate + phentermine. An excessively dangerous appetite-suppressant combination.
Prescrire Int; 2013 Mar; 22(136):61-4. PubMed ID: 23593686
[TBL] [Abstract][Full Text] [Related]
10. Phentermine/topiramate for the treatment of obesity.
Smith SM; Meyer M; Trinkley KE
Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
[TBL] [Abstract][Full Text] [Related]
11. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
Bays HE; Gadde KM
Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915
[TBL] [Abstract][Full Text] [Related]
12. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Kiortsis DN
Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
[TBL] [Abstract][Full Text] [Related]
13. Two anti-obesity hopefuls and their safety.
Bello NT; Campbell SC
Expert Opin Drug Saf; 2012 Sep; 11(5):681-3. PubMed ID: 22788876
[No Abstract] [Full Text] [Related]
14. Diet drugs Belviq and Qsymia receive FDA approval: what dentists need to know.
Wynn RL
Gen Dent; 2013; 61(1):11-3. PubMed ID: 23302354
[No Abstract] [Full Text] [Related]
15. Tolerability and safety of the new anti-obesity medications.
Hainer V; Aldhoon-Hainerová I
Drug Saf; 2014 Sep; 37(9):693-702. PubMed ID: 25096956
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of lorcaserin for the treatment of obesity.
Berlie HD; Hurren KM
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1053-9. PubMed ID: 23802690
[TBL] [Abstract][Full Text] [Related]
17. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
[TBL] [Abstract][Full Text] [Related]
18. 2 new drugs for weight loss.
Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487
[No Abstract] [Full Text] [Related]
19. The FDA's assessment of two drugs for chronic weight management.
Colman E; Golden J; Roberts M; Egan A; Weaver J; Rosebraugh C
N Engl J Med; 2012 Oct; 367(17):1577-9. PubMed ID: 23050510
[No Abstract] [Full Text] [Related]
20. ACS chemical neuroscience molecule spotlight on Qnexa.
Mercer SL
ACS Chem Neurosci; 2011 Apr; 2(4):183-4. PubMed ID: 22778866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]